Evidence map›Paper›PMID 35816124›Full record

ArticleJournal of managed care & specialty pharmacy2022

Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.

Kerry A Rogers, Xiaoxiao Lu, Bruno Emond, Aurélie Côté-Sergent, Frédéric Kinkead, Marie-Hélène Lafeuille, Patrick Lefebvre, Qing Huang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of managed care & specialty pharmacy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kerry A RogersDivision of Hematology, The Ohio State University, Columbus.
Xiaoxiao LuJanssen Scientific Affairs, LLC, Horsham, PA.
Bruno EmondAnalysis Group, Inc., Montréal, QC, Canada.
Aurélie Côté-SergentAnalysis Group, Inc., Montréal, QC, Canada.
Frédéric KinkeadAnalysis Group, Inc., Montréal, QC, Canada.
Marie-Hélène LafeuilleAnalysis Group, Inc., Montréal, QC, Canada.
Patrick LefebvreAnalysis Group, Inc., Montréal, QC, Canada.
Qing HuangJanssen Scientific Affairs, LLC, Horsham, PA.
Janssen Scientific Affairs (United States)The Ohio State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsLeukemia, Lymphocytic, Chronic, B-CellTumor Lysis SyndromeAdultFinancial StressHealth Care CostsHumansLenalidomideQuality of LifeRetrospective StudiesAntineoplastic AgentsLenalidomide

Identifiers

PMID35816124
PMCPMC12101563
OpenAlexW4285034472

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.